Table 1.
Clinical and laboratory characteristics of hepatocellular carcinoma patients and hsa-miR-21-5p expression
|
|
|
All patients
|
miR-21 low1
|
miR-21 high2
|
P
value
|
| Patient number: | 91 | 47 | 44 | ||
| Gender (n, %): | Women | 17 (18.7%) | 7 (14.9%) | 10 (22.7%) | 0.4231 |
| Men | 74 (81.3%) | 40 (85.1%) | 34 (77.3%) | ||
| Age in yr | mean ± SD | 67.91 ± 8.98 | 69.11 ± 8.84 | 66.64 ± 9.05 | 0.1912 |
| Etiology (n, %): | Alcohol abuse | 41 (45.1%) | 22 (46.8%) | 19 (43.2%) | 0.7560 |
| Viral hepatitis | 12 (13.2%) | 5 (10.6%) | 7 (15.9%) | ||
| NASH | 13 (14.3%) | 8 (17.0%) | 5 (11.4%) | ||
| Rare or other cause3 | 25 (27.5%) | 12 (25.5%) | 13 (29.5%) | ||
| BCLC stage (n, %): | A | 16 (17.6%) | 7 (14.9%) | 9 (20.5%) | 0.7787 |
| B | 37 (40.7%) | 20 (42.6%) | 17 (38.6%) | ||
| C + D | 38 (41.8%) | 20 (42.6%) | 18 (40.9%) | ||
| Child-Pugh score (n, %): | No liver cirrhosis | 16 (17.6%) | 8 (17.0%) | 8 (18.2%) | 0.7443 |
| A | 45 (49.5%) | 25 (53.2%) | 20 (45.5%) | ||
| B + C | 30 (33.0%) | 14 (29.8%) | 16 (36.4%) | ||
| Treatment (n, %)4: | Therapy naïve | 26 (28.6%) | 11 (23.4%) | 15 (34.1%) | 0.3535 |
| Pretreated | 65 (71.4%) | 36 (76.6%) | 29 (65.9%) | ||
| Ascites (n, %): | No ascites | 58 (63.7%) | 30 (63.8%) | 28 (63.6%) | 0.9999 |
| Ascites present | 33 (36.3%) | 17 (36.2%) | 16 (36.4%) | ||
| Bilirubin (µmol/L): | mean ± SD | 23.38 ± 31.73 | 24.27 ± 40.47 | 22.43 ± 18.78 | 0.7833 |
| AFP (ng/mL): | mean ± SD | 4593 ± 20162 | 540 ± 1533 | 8922 ± 28481 | 0.0469 |
| INR5: | mean ± SD | 1.076 ± 0.2127 | 1.034 ± 0.1450 | 1.122 ± 0.2611 | 0.0486 |
| Platelets (Gpt/L): | mean ± SD | 195.6 ± 118.7 | 182.7 ± 80.5 | 209.3 ± 149.0 | 0.2870 |
| ALAT (μmol/Ls): | mean ± SD | 0.7457 ± 0.4460 | 0.6955 ± 0.3425 | 0.7993 ± 0.5340 | 0.2697 |
| ASAT (μmol/Ls): | mean ± SD | 1.267 ± 1.041 | 1.040 ± 0.597 | 1.510 ± 1.330 | 0.0307 |
| Hemoglobin (mmol/L): | mean ± SD | 7.811 ± 1.254 | 7.655 ± 1.122 | 7.977 ± 1.375 | 0.2230 |
| Creatinine (µmol/L): | mean ± SD | 92.92 ± 67.95 | 102.3 ± 88.46 | 82.91 ± 33.08 | 0.1751 |
| Albumin (g/L): | mean ± SD | 36.29 ± 6.539 | 36.47 ± 5.668 | 36.10 ± 7.420 | 0.7938 |
miR-21 50% percentile.
miR-21 > 50% percentile.
Including hemochromatosis.
Patients with different kind of pretreatments (for example hepatic resection, transarterial chemoembolization, selective internal radiation therapy and sorafenib) were included.
For 30 patients we obtained no exact laboratory value of the International Normalized Ratio (only < 1.5). For these patients, we calculated the International Normalized Ratio based on the Quick. P values were calculated with unpaired t-test, Fisher’s exact test, and χ2 test as appropriate. AFP: Alpha-fetoprotein; ALAT: Alanine aminotransferase; ASAT: Aspartate aminotransferase; BCLC: Barcelona Clinic Liver Cancer; INR: International Normalized Ratio; NASH: Non-alcoholic steatohepatitis; SD: Standard deviation.